Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Historical Holders from Q1 2016 to Q3 2025

Symbol: CRVS on Nasdaq
Type / Class: Equity / Common Stock
Shares outstanding: 74,361,296
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 41,673,686
Holdings value: $307,002,895
% of all portfolios: 0%
Number of holders: 101
Number of buys: 55
Number of sells: -30
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Filer	Ownership	Change %	Holdings Value	Nb Shares	Change %	Reporting Name	Report Period
ORBIMED ADVISORS LLC	12.2%	-11.4%	$35,423,231	9,785,423	0%	ORBIMED ADVISORS LLC	12 May 2025
MILLER RICHARD A MD	7.7%		$18,897,732	5,220,368		Richard A. Miller	31 Dec 2024
BlackRock, Inc.	5.4%		$29,594,309	4,015,510		BlackRock, Inc.	30 Sep 2025

Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	41,673,686	$307,002,895	+$4,353,875	$1,227,842	$1,459,997	$7.37	101
2025 Q2	41,781,497	$167,123,225	+$27,653,733	$903,245	$392,614	$4	92
2025 Q1	36,268,523	$115,333,082	-$7,370,970	$1,076,864	$4,357,820	$3.18	87
2024 Q4	37,723,156	$201,818,514	+$34,704,752	$6,240,775	$14,733,900	$5.35	85
2024 Q3	30,026,264	$158,538,176	+$12,733,385	$443,271	$5,587,417	$5.28	61
2024 Q2	27,591,708	$50,216,835	+$17,655,345	$54,236	$41,678	$1.82	46
2024 Q1	17,899,766	$31,860,771	-$2,279,392	$53,756	$53,222	$1.78	46
2023 Q4	19,183,314	$33,762,501	+$90,871	$136,576	$37,840	$1.76	46
2023 Q3	19,186,334	$28,011,450	-$1,230,958	$102,930	$70,226	$1.46	52
2023 Q2	19,491,995	$44,633,999	+$707,708	$255,327	$133,488	$2.29	51
2023 Q1	20,767,710	$18,897,208	-$183,902	$0	$10,000	$0.91	35
2022 Q4	21,363,573	$18,157,963	-$606,364	$935	$9,435	$0.85	38
2022 Q3	22,082,952	$18,073,081	-$3,458,421	$0	$10,000	$0.8183	38
2022 Q2	25,594,950	$25,339,212	-$3,279,778	$35,000	$36,000	$0.99	39
2022 Q1	27,387,121	$44,913,000	-$1,201,434	$106,000	$153,000	$1.64	52
2021 Q4	27,678,421	$66,701,000	-$7,831,144	$331,000	$307,000	$2.41	58
2021 Q3	28,180,241	$136,388,000	+$22,907,893	$2,267,000	$5,572,000	$4.84	55
2021 Q2	23,673,230	$63,207,000	+$8,569,595	$245,000	$79,000	$2.67	44
2021 Q1	20,393,400	$62,807,000	+$12,093,812	$435,000	$78,000	$3.08	45
2020 Q4	16,311,910	$58,071,014	-$3,250,489	$129,000	$224,000	$3.56	34
2020 Q3	17,216,699	$69,036,016	-$11,684,715	$3,000	$195,000	$4.01	33
2020 Q2	20,440,680	$55,598,011	-$392,205			$2.72	34
2020 Q1	20,651,240	$43,573,167	-$3,308,904			$2.11	36
2019 Q4	20,779,789	$113,038,430	-$10,373,847			$5.44	35
2019 Q3	22,891,685	$68,903,436	-$4,060,912			$3.01	34
2019 Q2	24,342,578	$90,952,754	-$1,503,000			$3.74	43
2019 Q1	24,763,106	$99,529,635	-$1,002,484			$4.02	56
2018 Q4	25,129,757	$92,163,767	-$1,838,747			$3.67	60
2018 Q3	25,496,765	$218,762,586	-$3,322,901			$8.58	60
2018 Q2	25,906,899	$284,454,314	+$6,770,964			$10.98	56
2018 Q1	25,285,587	$287,758,705	+$90,614,709			$11.53	54
2017 Q4	17,418,578	$180,457,571	-$3,160,000			$10.36	53
2017 Q3	17,544,055	$279,715,086	+$1,015,923			$15.94	52
2017 Q2	17,504,516	$211,804,598	-$2,803,453			$12.1	48
2017 Q1	17,335,240	$360,050,125	+$9,744,515			$20.77	52
2016 Q4	17,484,501	$250,048,615	+$17,391,608			$14.3	53
2016 Q3	16,266,787	$267,555,203	-$17,049,726			$16.45	44
2016 Q2	14,645,573	$208,464,147	+$13,774,406			$14.26	43
2016 Q1	13,758,120	$199,086,000	+$197,418,000			$14.5	31